Abstract:Cancer arises from the accumulation of genetic alterations, leading to the production of mutant proteins processed and presented as neoantigens on the surface of malignant cells. These can be derived from missense mutations or large insertions, deletions or translocations that produce indels and/or gene fusions. A major hurdle in developing cell-based therapies that engage the immune system against targets preferentially expressed on tumor cells is our inability to prioritize neoantigens due to insufficient knowledge of what drives immunogenicity. Accumulating evidence suggests CD8+ T cells recognize and mount effective responses against neoepitopes across various cancers, and both immune- and tumor-centric parameters play a role in this. However, it isn't known how the TCR repertoire drives antitumor responses, whether different patients with the same cancer type and similar HLAs generate comparable responses, or if differences in TCR specificity against conserved neoepitopes can be exploited to generate effective TCR-T cell-based therapies. To address these shortcomings and provide additional therapeutic options for patients with cancer, the goal of this research was to comprehensively assess the factors contributing to differences in tumor immunogenicity across different classes of antigens and define the principles of CD8+ T cell immune recognition that shape these responses. We hypothesized that different classes of antigens would have different peptide affinities and stabilities and in turn, affect the diversity of the naïve TCR repertoire. Furthermore, TCRs whose cognate antigen is highly dissimilar to self would have a higher probability of generation (Pgen). To test this, we performed peptide exchange assays using antigen presenting beads expressing HLA-A*02:01 to measure peptide-HLA (pHLA) affinity and stability. Naïve CD8+ T cells were then isolated from healthy donor PBMCs expressing HLA-A*02:01 and co-cultured with matched monoallelic K562 cells or autologous dendritic cells pulsed with viral and cancer antigens for a two-week period. On day 14, scRNA-seq and scTCR-seq were performed to characterize CD8+ transcriptional profiles, TCR diversity, and Pgen. Interestingly, our initial studies indicated that gene fusions, which display a greater distance from self than SNVs, have greater exchange rates, affinity, and stability compared to SNVs, but similar to viral antigens. While all antigens were able to induce CD8+ T cell expansion in co-culture assays, gene fusions and viral antigens generated the greatest frequency of antigen-specific CD8+ T cells and these TCRs tended to have a higher Pgen suggesting there may be an evolutionarily conserved mechanism in how specific TCR clonotypes are generated against evolutionarily encountered antigens and/or antigens with a high dissimilarity to self. Surprisingly, the number and diversity of the neoantigen-specific responses were heterogeneous and, in some cases, unique to the donor, which suggests there is a difference in donors' ability to generate private vs public TCRs. Citation Format: Jessica L. Schmeling, Anthony E. Zamora. Tumor- and T-cell-centric parameters shape the immunogenicity of cancer neoantigens and determine productive antitumor CD8+ T cell responses [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B045.

A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

An immunogenic personal neoantigen vaccine for patients with melanoma

Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma

425 A Novel Dendritic Cell Vaccine Utilizing Mannan Anchored to Irradiated Tumor Cells in the Presence of Immune Adjuvants

Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience

Therapeutic Anti-Tumor Efficacy of DC-Based Vaccines Targeting TME-Associated Antigens Is Improved When Combined with a Chemokine-Modulating Regimen and/or Anti-PD-L1

The Immunogenicity and Anti-tumor Efficacy of a Rationally Designed Neoantigen Vaccine for B16F10 Mouse Melanoma

Structural basis for self-discrimination by neoantigen-specific TCRs

Level of expression of MHCI-presented neoepitopes influences tumor rejection by neoantigen-specific CD8+ T cells

Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma

Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy

Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines

Synthetic Melanin Acts as Efficient Peptide Carrier in Cancer Vaccine Strategy

Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma

Targeting pan-tumor antigens to activating Fcγ receptors generates a novel dendritic cell tumor vaccine

Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells

Abstract B045: Tumor- and T-cell-centric parameters shape the immunogenicity of cancer neoantigens and determine productive antitumor CD8+ T cell responses

H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patient

Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report